Does the media favor FBIO or EBS?

In the previous week, Fortress Biotech and Fortress Biotech both had 1 articles in the media. Fortress Biotech's average media sentiment score of 0.00 equaled Emergent Biosolutions'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Emergent Biosolutions 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VNDA or FBIO?

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 1 mentions for Fortress Biotech. Vanda Pharmaceuticals' average media sentiment score of 0.53 beat Fortress Biotech's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FBIO or SABS?

In the previous week, SAB Biotherapeutics had 5 more articles in the media than Fortress Biotech. MarketBeat recorded 6 mentions for SAB Biotherapeutics and 1 mentions for Fortress Biotech. SAB Biotherapeutics' average media sentiment score of 1.04 beat Fortress Biotech's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SAB Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is FBIO or AGEN more profitable?

Fortress Biotech has a net margin of 193.12% compared to Agenus' net margin of 50.49%. Fortress Biotech's return on equity of 109.66% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Fortress Biotech 193.12% 109.66% 45.56% Agenus 50.49% -31.66% 42.71%

Does the media prefer FBIO or AGEN?

In the previous week, Agenus had 5 more articles in the media than Fortress Biotech. MarketBeat recorded 6 mentions for Agenus and 1 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Agenus' score of -0.04 indicating that Fortress Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agenus 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is FBIO or CDXS more profitable?

Fortress Biotech has a net margin of 193.12% compared to Codexis' net margin of -40.97%. Fortress Biotech's return on equity of 109.66% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Fortress Biotech 193.12% 109.66% 45.56% Codexis -40.97% -68.09% -23.72%

Does the media prefer FBIO or CDXS?

In the previous week, Codexis had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Codexis and 1 mentions for Fortress Biotech. Codexis' average media sentiment score of 0.47 beat Fortress Biotech's score of 0.00 indicating that Codexis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Codexis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fortress Biotech (FBIO) Competitors

$2.76 -0.37 (-11.82%)

Closing price 04:00 PM Eastern

Extended Trading

$2.82 +0.06 (+1.99%)

As of 07:34 PM Eastern

Compare

FBIO vs. EBS, VNDA, SABS, AGEN, and CDXS

Should you buy Fortress Biotech stock or one of its competitors? MarketBeat compares Fortress Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fortress Biotech include Emergent Biosolutions (EBS), Vanda Pharmaceuticals (VNDA), SAB Biotherapeutics (SABS), Agenus (AGEN), and Codexis (CDXS).

How does Fortress Biotech compare to Emergent Biosolutions?

Fortress Biotech (NASDAQ:FBIO) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

In the previous week, Fortress Biotech and Fortress Biotech both had 1 articles in the media. Fortress Biotech's average media sentiment score of 0.00 equaled Emergent Biosolutions'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent Biosolutions	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fortress Biotech has a net margin of 193.12% compared to Emergent Biosolutions' net margin of -1.27%. Fortress Biotech's return on equity of 109.66% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Emergent Biosolutions	-1.27%	10.76%	4.22%

Fortress Biotech presently has a consensus target price of $17.00, suggesting a potential upside of 515.94%. Emergent Biosolutions has a consensus target price of $12.00, suggesting a potential upside of 62.05%. Given Fortress Biotech's higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Emergent Biosolutions has higher revenue and earnings than Fortress Biotech. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.45	$6.82M	$3.17	0.87
Emergent Biosolutions	$742.90M	0.51	$52.60M	-$0.28	N/A

Fortress Biotech has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Fortress Biotech beats Emergent Biosolutions on 9 of the 14 factors compared between the two stocks.

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Vanda Pharmaceuticals has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 1 mentions for Fortress Biotech. Vanda Pharmaceuticals' average media sentiment score of 0.53 beat Fortress Biotech's score of 0.00 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fortress Biotech has a net margin of 193.12% compared to Vanda Pharmaceuticals' net margin of -109.99%. Fortress Biotech's return on equity of 109.66% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-109.99%	-32.26%	-23.43%
Fortress Biotech	193.12%	109.66%	45.56%

Fortress Biotech has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$217.78M	1.44	-$220.47M	-$4.05	N/A
Fortress Biotech	$63.26M	1.45	$6.82M	$3.17	0.87

Vanda Pharmaceuticals presently has a consensus price target of $14.30, indicating a potential upside of 173.42%. Fortress Biotech has a consensus price target of $17.00, indicating a potential upside of 515.94%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Fortress Biotech beats Vanda Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to SAB Biotherapeutics?

Fortress Biotech (NASDAQ:FBIO) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, SAB Biotherapeutics had 5 more articles in the media than Fortress Biotech. MarketBeat recorded 6 mentions for SAB Biotherapeutics and 1 mentions for Fortress Biotech. SAB Biotherapeutics' average media sentiment score of 1.04 beat Fortress Biotech's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SAB Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has a net margin of 193.12% compared to SAB Biotherapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 109.66% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Fortress Biotech has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

SAB Biotherapeutics has lower revenue, but higher earnings than Fortress Biotech. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.45	$6.82M	$3.17	0.87
SAB Biotherapeutics	$1.32M	219.53	$13.27M	-$2.11	N/A

Fortress Biotech presently has a consensus target price of $17.00, suggesting a potential upside of 515.94%. SAB Biotherapeutics has a consensus target price of $12.00, suggesting a potential upside of 216.62%. Given Fortress Biotech's higher possible upside, analysts clearly believe Fortress Biotech is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Fortress Biotech beats SAB Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Agenus?

Fortress Biotech (NASDAQ:FBIO) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Fortress Biotech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Agenus has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

In the previous week, Agenus had 5 more articles in the media than Fortress Biotech. MarketBeat recorded 6 mentions for Agenus and 1 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Agenus' score of -0.04 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agenus	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 6.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Fortress Biotech has higher earnings, but lower revenue than Agenus. Fortress Biotech is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.45	$6.82M	$3.17	0.87
Agenus	$114.20M	3.06	$120K	$1.59	4.92

Fortress Biotech has a net margin of 193.12% compared to Agenus' net margin of 50.49%. Fortress Biotech's return on equity of 109.66% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Agenus	50.49%	-31.66%	42.71%

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 515.94%. Agenus has a consensus price target of $22.00, indicating a potential upside of 181.33%. Given Fortress Biotech's higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Fortress Biotech beats Agenus on 9 of the 14 factors compared between the two stocks.

How does Fortress Biotech compare to Codexis?

Fortress Biotech (NASDAQ:FBIO) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Fortress Biotech has a net margin of 193.12% compared to Codexis' net margin of -40.97%. Fortress Biotech's return on equity of 109.66% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Codexis	-40.97%	-68.09%	-23.72%

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 3.5% of Codexis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 515.94%. Codexis has a consensus price target of $5.00, indicating a potential upside of 244.83%. Given Fortress Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Fortress Biotech is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Fortress Biotech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Codexis has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market.

Fortress Biotech has higher earnings, but lower revenue than Codexis. Codexis is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.45	$6.82M	$3.17	0.87
Codexis	$70.39M	1.87	-$43.97M	-$0.37	N/A

In the previous week, Codexis had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Codexis and 1 mentions for Fortress Biotech. Codexis' average media sentiment score of 0.47 beat Fortress Biotech's score of 0.00 indicating that Codexis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortress Biotech beats Codexis on 11 of the 16 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBIO vs. The Competition

Export

Metric	Fortress Biotech	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$103.98M	$11.60B	$6.86B	$12.45B
Dividend Yield	N/A	2.73%	2.60%	10.03%
P/E Ratio	0.87	793.98	280.72	24.99
Price / Sales	1.45	731.33	588.04	90.94
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	1.38	10.39	11.02	6.21
Net Income	$6.82M	$2.80B	$3.48B	$347.49M
7 Day Performance	-15.60%	0.30%	0.56%	0.89%
1 Month Performance	-9.21%	-3.70%	-4.14%	-3.60%
1 Year Performance	52.49%	156.59%	63.23%	20.46%

Fortress Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBIO Fortress Biotech	2.1755 of 5 stars	$2.76 -11.8%	$17.00 +515.9%	+72.9%	$103.98M	$63.26M	0.87	170	Gap Down High Trading Volume
EBS Emergent Biosolutions	1.7181 of 5 stars	$7.32 +0.8%	$12.00 +64.0%	+28.0%	$374.59M	$742.90M	N/A	2,420	Upcoming Earnings
VNDA Vanda Pharmaceuticals	2.7779 of 5 stars	$5.22 +0.8%	$14.30 +173.9%	+21.7%	$311.50M	$216.10M	N/A	290
SABS SAB Biotherapeutics	3.0303 of 5 stars	$3.44 -2.0%	$12.00 +248.8%	+60.1%	$268.39M	$1.32M	N/A	140	News Coverage Positive News Upcoming Earnings Analyst Downgrade
AGEN Agenus	3.4499 of 5 stars	$6.13 +2.5%	$30.00 +389.4%	+39.9%	$267.62M	$114.20M	3.86	440	Upcoming Earnings Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBIO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortress Biotech (FBIO) Competitors

FBIO vs. EBS, VNDA, SABS, AGEN, and CDXS

How does Fortress Biotech compare to Emergent Biosolutions?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Summary

How does Fortress Biotech compare to SAB Biotherapeutics?

Summary

How does Fortress Biotech compare to Agenus?

Summary

How does Fortress Biotech compare to Codexis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortress Biotech (FBIO) Competitors

FBIO vs. EBS, VNDA, SABS, AGEN, and CDXS

How does Fortress Biotech compare to Emergent Biosolutions?

Does the media favor FBIO or EBS?

Is FBIO or EBS more profitable?

Do analysts rate FBIO or EBS?

Which has stronger earnings & valuation, FBIO or EBS?

Which has more volatility and risk, FBIO or EBS?

Do insiders and institutionals have more ownership in FBIO or EBS?

Summary

How does Fortress Biotech compare to Vanda Pharmaceuticals?

Which has more volatility & risk, VNDA or FBIO?

Do insiders & institutionals have more ownership in VNDA or FBIO?

Does the media refer more to VNDA or FBIO?

Is VNDA or FBIO more profitable?

Which has preferable valuation & earnings, VNDA or FBIO?

Do analysts rate VNDA or FBIO?

Summary

How does Fortress Biotech compare to SAB Biotherapeutics?

Do insiders and institutionals have more ownership in FBIO or SABS?

Does the media favor FBIO or SABS?

Is FBIO or SABS more profitable?

Which has more risk and volatility, FBIO or SABS?

Which has higher valuation and earnings, FBIO or SABS?

Do analysts rate FBIO or SABS?

Summary

How does Fortress Biotech compare to Agenus?

Which has more volatility & risk, FBIO or AGEN?

Does the media prefer FBIO or AGEN?

Do institutionals & insiders believe in FBIO or AGEN?

Which has stronger earnings and valuation, FBIO or AGEN?

Is FBIO or AGEN more profitable?

Do analysts recommend FBIO or AGEN?

Summary

How does Fortress Biotech compare to Codexis?

Is FBIO or CDXS more profitable?

Do insiders and institutionals believe in FBIO or CDXS?

Do analysts rate FBIO or CDXS?

Which has more risk and volatility, FBIO or CDXS?

Which has better earnings and valuation, FBIO or CDXS?

Does the media prefer FBIO or CDXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools